Hengrui Medicine (01276): SHR-4610 Injection and other drugs receive drug clinical trial approval notices

Zhitong Finance APP News, Hengrui Pharmaceuticals (01276) announced that recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company") and its subsidiaries Suzhou Shengdia Biopharmaceutical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceuticals Co., Ltd. received the Drug Clinical Trial Approval Notices approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for SHR-4610 Injection, SHR-9839 (sc) for Injection, SHR-A2102 for Injection, SHR-4849 Injection, SHR-7787 Injection, and HRS-4508 Tablets, and will commence clinical trials in the near future.